Dividend Declaration

BIOPHARMA CREDIT PLC 

("BIOPHARMA CREDIT" OR THE "COMPANY") 

DIVIDEND DECLARATION

BioPharma Credit PLC (LSE: BPCR), the specialist life sciences debt investor, is pleased to declare an interim dividend in respect of the financial period ending 31 December 2021 of $0.01750000 per ordinary share, payable on 31 March 2022 to ordinary shareholders on the register as at 4 March 2022. The Company has chosen to designate part of this interim dividend as an interest distribution. The dividend will be paid as 0.01482709 cents per share as an interest payment and 0.00267291 cents per share as an ordinary dividend. Shareholders in receipt of such a dividend will be treated for UK tax purposes as though they have received a payment of interest in respect of the interest distribution element of this dividend. This will result in a reduction in the corporation tax payable by the Company.

The Company is currently paying and continues to target a 7 cent annual dividend per ordinary share.

The default payment for dividends is in US dollars. However, shareholders can elect to have dividends paid in sterling (GBP) and the option to elect a sterling dividend payment for this dividend will be available to shareholders until 4 March 2022 (the "Election Date").

Further details together with a copy of the Dividend Currency Election Form, which should be sent to Link Group, 10th Floor, Central Square, 29 Wellington Street, Leeds LS1 4DL when completed, will be available on the Group's website shortly at www.bpcruk.com/investor-materials. CREST shareholders must elect via CREST.

LEI: 213800AV55PYXAS7SY24

-Ends-

Link Company Matters Limited

Company Secretary

24 February 2022

Enquiries:

Buchanan

David Rydell / Mark Court / Jamie Hooper / Henry Wilson

+44 (0)20 7466 5000

[email protected]

Notes to Editors:

BioPharma Credit PLC is London's only listed specialist investor in debt from the life sciences industry and joined the LSE on 27 March 2017. The Company seeks to provide long-term shareholder returns, principally in the form of sustainable income distributions from exposure to the life sciences industry. The Company seeks to achieve this objective primarily through investments in debt assets secured by royalties or other cash flows derived from the sales of approved life sciences products.